Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

Affiliations

¹ Département d'Oncologie Médicale, Institut du Cancer de Montpellier, Montpellier, France.
² University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, Germany.

Comment

Antoine Adenis et al. JAMA Oncol. 2018.

. 2018 Jun 1;4(6):887-888.

doi: 10.1001/jamaoncol.2018.0239.

¹ Département d'Oncologie Médicale, Institut du Cancer de Montpellier, Montpellier, France.
² University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, Germany.

No abstract available

Comment in

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer-Reply.
Suntharalingam M, Winter K, Ilson D. Suntharalingam M, et al. JAMA Oncol. 2018 Jun 1;4(6):888-889. doi: 10.1001/jamaoncol.2018.0242. JAMA Oncol. 2018. PMID: 29596545 Free PMC article. No abstract available.

Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Suntharalingam M, et al. JAMA Oncol. 2017 Nov 1;3(11):1520-1528. doi: 10.1001/jamaoncol.2017.1598. JAMA Oncol. 2017. PMID: 28687830 Free PMC article. Clinical Trial.